CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

(Alliance News) - GSK announced a partnership with China's Hengrui, Cranswick said it expects results in line with market expectations, while STV warned of an annual outcome below consensus. Here is ...

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

GSK GSK 0.99 % increase; green up pointing triangle plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

We aim to explore its current performance. Present Market Standing of GSK With a volume of 19,701,072, the price of GSK is up 5.97% at $40.29.

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

This article was corrected at 0907 GMT to reflect GSK's core earnings per share fell 10% at constant currencies to 23.2 pence, above analysts' expectations of 20.6 pence.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was withdrawn several years ago.